Viewing Study NCT01300351


Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2026-02-11 @ 12:00 PM
Study NCT ID: NCT01300351
Status: COMPLETED
Last Update Posted: 2015-04-24
First Post: 2011-02-17
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced breast cancer View
None metastatic breast cancer View